Drug intelligence / Profile preview

C04

Development stage: Unknown

Overview

The identifier 'C04' is used as a code name for multiple distinct investigational drug candidates within the provided context. These include an anti-FcγRI monoclonal antibody being developed for autoimmune disorders, a 5-Fluorouracil (5-FU) hybrid compound acting as a thymidylate synthase inhibitor for non-small cell lung cancer, and an amino-conjugated bile acid derivative being investigated for non-alcoholic steatohepatitis (NASH). Due to this ambiguity, specific details regarding a single drug 'C04' cannot be provided.

Targets

VEGFR4 (Vascular endothelial growth factor Receptor-3)Focal adhesion kinase (FAK)–Vascular endothelial growth factor receptor 3 (VEGFR-3) protein–protein interfaceFAK (Focal adhesion kinase)

Beyond the preview

Go deeper on C04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C04.

Explore the full profile